FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3148681902> ?p ?o ?g. }

• W3148681902 endingPage "175883592110069" @default.
• W3148681902 startingPage "175883592110069" @default.
• W3148681902 abstract "Currently, there are many approaches available for neoadjuvant therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer that improve therapeutic efficacy but are also controversial. We conducted a two-step Bayesian network meta-analysis (NMA) to compare odds ratios (ORs) for pathologic complete response (PCR) and safety endpoints.The Cochrane Central Register of Controlled Trials, PubMed, Embase, and online abstracts from the American Society of Clinical Oncology and San Antonio Breast Cancer Symposium were searched comprehensively and systematically. Phase II/III randomised clinical trials for targeted therapy in at least one arm were included.A total of 9779 published manuscripts were identified, and 36 studies including 10,379 patients were finally included in our analysis. The NMA of PCR showed that dual-target therapy is better than single-target therapy and combination chemotherapy is better than monochemotherapy. However, anthracycline did not bring extra benefits, whether combined with dual-target therapy or single-target therapy. On the other hand, the addition of endocrine therapy in the HER2-positive, hormone receptor (HR)-positive subgroup might have additional beneficial effects but without significant statistical difference. By performing a conjoint analysis of the PCR rate and safety endpoints, we found that 'trastuzumab plus pertuzumab' and 'T-DM1 containing regimens' were well balanced in terms of efficacy and toxicity in all target regimens.In summary, trastuzumab plus pertuzumab-based dual-target therapy with combination chemotherapy regimens showed the highest efficacy of all optional regimens. They also achieved the best balance between efficacy and toxicity. As our study showed that anthracycline could be replaced by carboplatin, we strongly recommended TCbHP as the preferred choice for neoadjuvant treatment of HER2-positive breast cancer. We also look forward to the potential value of T-DM1 in improving outcomes, which needs further study in future trials." @default.
• W3148681902 created "2021-04-13" @default.
• W3148681902 creator A5009503827 @default.
• W3148681902 creator A5018978373 @default.
• W3148681902 creator A5025624287 @default.
• W3148681902 creator A5034618391 @default.
• W3148681902 creator A5042241049 @default.
• W3148681902 creator A5045771123 @default.
• W3148681902 creator A5048223283 @default.
• W3148681902 creator A5073501391 @default.
• W3148681902 creator A5080229461 @default.
• W3148681902 date "2021-01-01" @default.
• W3148681902 modified "2023-10-06" @default.
• W3148681902 title "Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis" @default.
• W3148681902 cites W1517555081 @default.
• W3148681902 cites W1781991762 @default.
• W3148681902 cites W1987326983 @default.
• W3148681902 cites W1992234802 @default.
• W3148681902 cites W2006985579 @default.
• W3148681902 cites W2010699829 @default.
• W3148681902 cites W2043506695 @default.
• W3148681902 cites W2046376183 @default.
• W3148681902 cites W2046958698 @default.
• W3148681902 cites W2048658106 @default.
• W3148681902 cites W2055235037 @default.
• W3148681902 cites W2066986956 @default.
• W3148681902 cites W2072651545 @default.
• W3148681902 cites W2075894019 @default.
• W3148681902 cites W2080514770 @default.
• W3148681902 cites W2095861620 @default.
• W3148681902 cites W2098775844 @default.
• W3148681902 cites W2107602135 @default.
• W3148681902 cites W2111578514 @default.
• W3148681902 cites W2117984780 @default.
• W3148681902 cites W2123591186 @default.
• W3148681902 cites W2125239609 @default.
• W3148681902 cites W2141232624 @default.
• W3148681902 cites W2141393790 @default.
• W3148681902 cites W2151262170 @default.
• W3148681902 cites W2155560234 @default.
• W3148681902 cites W2155794195 @default.
• W3148681902 cites W2162982444 @default.
• W3148681902 cites W2318605753 @default.
• W3148681902 cites W2346278060 @default.
• W3148681902 cites W2379981061 @default.
• W3148681902 cites W2471493685 @default.
• W3148681902 cites W2555279718 @default.
• W3148681902 cites W2588881638 @default.
• W3148681902 cites W2591900900 @default.
• W3148681902 cites W2613098450 @default.
• W3148681902 cites W2620735862 @default.
• W3148681902 cites W2624590002 @default.
• W3148681902 cites W2766626616 @default.
• W3148681902 cites W2768649895 @default.
• W3148681902 cites W2768980003 @default.
• W3148681902 cites W2785217251 @default.
• W3148681902 cites W2795193052 @default.
• W3148681902 cites W2799775876 @default.
• W3148681902 cites W2806386505 @default.
• W3148681902 cites W2820616462 @default.
• W3148681902 cites W2885502120 @default.
• W3148681902 cites W2892706993 @default.
• W3148681902 cites W2899659781 @default.
• W3148681902 cites W2902218997 @default.
• W3148681902 cites W2907776942 @default.
• W3148681902 cites W2923062528 @default.
• W3148681902 cites W2947469974 @default.
• W3148681902 cites W2947774574 @default.
• W3148681902 cites W2948405934 @default.
• W3148681902 cites W2969604985 @default.
• W3148681902 cites W2971863214 @default.
• W3148681902 cites W2981669117 @default.
• W3148681902 cites W2982154937 @default.
• W3148681902 cites W2994601580 @default.
• W3148681902 cites W2995808512 @default.
• W3148681902 cites W2998950563 @default.
• W3148681902 cites W3000085197 @default.
• W3148681902 cites W3004428416 @default.
• W3148681902 cites W3010197652 @default.
• W3148681902 cites W3011912378 @default.
• W3148681902 cites W3028719789 @default.
• W3148681902 cites W3029492498 @default.
• W3148681902 cites W3031350720 @default.
• W3148681902 cites W3032387960 @default.
• W3148681902 cites W3088174704 @default.
• W3148681902 cites W3104822654 @default.
• W3148681902 cites W4243460686 @default.
• W3148681902 cites W4254815115 @default.
• W3148681902 doi "https://doi.org/10.1177/17588359211006948" @default.
• W3148681902 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8020239" @default.
• W3148681902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33868462" @default.
• W3148681902 hasPublicationYear "2021" @default.
• W3148681902 type Work @default.
• W3148681902 sameAs 3148681902 @default.
• W3148681902 citedByCount "8" @default.
• W3148681902 countsByYear W31486819022022 @default.
• W3148681902 countsByYear W31486819022023 @default.
• W3148681902 crossrefType "journal-article" @default.

• next